Sign In
Buy TIL
$7.12
-0.0200 (-0.280%)
At Close: Jul 31, 2026
Instil Bio shares slide on discontinuation of lead clinical programs
04:11pm, Tuesday, 06'th Jan 2026
Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to discontinue development of its lead clinical assets AXN-2510 and AXN-27M and to terminate its partn
Instil Bio Pulls Plug On Lead Drug Development
12:31pm, Tuesday, 06'th Jan 2026
Instil Bio, Inc. (NASDAQ: TIL) stock is trading lower on Tuesday. Axion Bio Inc., a wholly-owned subsidiary of Instil, decided to discontinue clinical development of AXN-2510.
Instil Bio shares slide on discontinuation of lead clinical programs
11:07am, Tuesday, 06'th Jan 2026
Instil Bio (NASDAQ:TIL) shares plummeted 46% to about $7 after the company announced its decision to discontinue development of its lead clinical assets...
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to disconti
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Thursday, 13'th Nov 2025
DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSC
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
06:00am, Wednesday, 13'th Aug 2025
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in t
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
01:00pm, Friday, 20'th Jun 2025
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
10:56am, Monday, 16'th Jun 2025
The mean of analysts' price targets for Instil Bio (TIL) points to a 246.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analy
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
07:00am, Wednesday, 11'th Jun 2025
DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
01:06pm, Wednesday, 04'th Jun 2025
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
07:00am, Monday, 02'nd Jun 2025
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today an
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
07:00am, Friday, 30'th May 2025
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that
